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As plans for malaria eradication continue, a vaccine target-
ing Plasmodium vivax is of major importance due to the
fact that it is the most widely distributed human malaria
parasite in the world and the most difficult to eliminate
due to its ability to hide in the liver forming hypnozoites.
Malaria liver-stage vaccines are one of the leading strate-
gies and the only approach that has demonstrated com-
plete, sterile protection in clinical trials. We have
developed vaccine candidates using platforms suitable for
human use, consisting of virus-like particles (VLPs), chim-
panzee adenovirus (ChAd63) and modified vaccinia
Ankara (MVA) containing malaria pre-erythrocytic anti-
gens, and several novel challenge models using transgenic
mouse-malaria P. berghei parasites expressing P. vivax
antigens that permit the assessment of vaccine efficacy in
small animal models, thus providing a suitable platform
for vaccine development in non-endemic countries and
permitting the progress of vaccines that rely on assessment
of efficacy rather than measurement of immunogenicity, in
the absence of a conclusive correlate of protection.
We present results of two leading malaria vaccine candi-
dates, a universal vivax circumsporozoite antigen (PvCSP)
and the thrombospondin-related adhesion protein
(PvTRAP) to create recombinant adenovirus, MVA and a
platform consisting of VLPs to enhance efficacy of our
malaria vaccines. All have been tested using transgenic
parasites expressing the P. vivax CSP VK210, VK247 and
TRAP, thus permitting the assessment of protective efficacy
in various mouse strains and yielding important information
to address cross protection against CSP using a challenge
with VK210 or VK247 parasites in mice vaccinated with
homologous, heterologous or chimeric CSP antigens.
Our studies indicate that our vaccines are able to induce
outstanding T-cell responses and antibody titers that can
protect against a stringent challenge with high doses of
fully virulent transgenic parasites in mice. Our groups are
currently committing a substantial effort in developing
further transgenic parasites to allow the discovery of new
vaccine candidates able to afford protection.
Authors’ details
1University of Oxford, Oxford, UK. 2Leiden University Medical Center, Leiden,
The Netherlands.
Published: 22 September 2014
doi:10.1186/1475-2875-13-S1-P77
Cite this article as: Reyes-Sandoval et al.: Development of a Plasmodium
vivax malaria vaccine for clinical applications using transgenic parasites,
virus-like particles and recombinant viruses. Malaria Journal 2014 13
(Suppl 1):P77.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit1University of Oxford, Oxford, UK
Full list of author information is available at the end of the article
Reyes-Sandoval et al. Malaria Journal 2014, 13(Suppl 1):P77
http://www.malariajournal.com/content/13/S1/P77
© 2014 Reyes-Sandoval et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
